Observational studyEBioMedicine2023
Determinants of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study.
Observational study in EBioMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Treatment of post-treatment Lyme disease symptoms-a systematic review.European journal of neurology · 2024Pooled it
- Lyme borreliosis.Nature reviews. Disease primers · 2026Review
- Article
- Nonspecific Symptoms Attributable to Lyme Disease in High-Incidence Areas, United States, 2017-2021.Emerging infectious diseases · 2025Article
- Prevalence and clinical characteristics of Norwegians who report persistent health complaints attributed to tick bites or tick-borne diseases.BMC infectious diseases · 2025Article
- Rabies virus-vectored Lyme disease vaccine provides long-term protection against tick-transmitted Borrelia burgdorferi.NPJ vaccines · 2025Article
- Temporal Dynamic Interplay of Mouse Proteome during ProtozoanJournal of proteome research · 2025Article
- Persistent self-reported health complaints in Norwegians who attribute their symptoms to tick bites or tick-borne disease- a cross-sectional controlled study.BMC infectious diseases · 2025Article
- The peptidoglycan ofScience translational medicine · 2025Article
- Understanding the Perspectives, Experiences, Beliefs, and Knowledge of Health Care Practitioners on the Diagnosis and Treatment of Lyme Disease in Canada.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2025Article
- Residual Symptoms and Quality of Life After Treated Lyme Neuroborreliosis: Case-Control Study (QoLYME).Open forum infectious diseases · 2025Article
- Clinical and laboratory characteristics during a 1-year follow-up in European Lyme neuroborreliosis: A prospective cohort study.European journal of neurology · 2024Article
- Late-stage borreliosis and substance abuse.Heliyon · 2024Article
- Genome-wide analyses in Lyme borreliosis: identification of a genetic variant associated with disease susceptibility and its immunological implications.BMC infectious diseases · 2024Article
- Psychological burden associated with incident persistent symptoms and their evolution during the COVID-19 pandemic: a prospective population-based study.BMJ mental health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients treated for Lyme borreliosis (LB) frequently report persistent symptoms. Little is known about risk factors and etiology.
methodsIn a prospective observational cohort study with a follow-up of one year, we assessed a range of microbiological, immunological, genetic, clinical, functional, epidemiological, psychosocial and cognitive-behavioral variables as determinants of persistent symptoms after treatment for LB. Between 2015 and 2018 we included 1135 physician-confirmed LB patients at initiation of antibiotic therapy, through clinical LB centers and online self-registration. Two reference cohorts of individuals without LB (n = 4000 and n = 2405) served as a control. Prediction analyses and association studies were used to identify determinants, as collected from online questionnaires (three-monthly) and laboratory tests (twice).
findingsMain predictors of persistent symptoms were baseline poorer physical and social functioning, higher depression and anxiety scores, more negative illness perceptions, comorbidity, as well as fatigue, cognitive impairment, and pain in 295 patients with persistent symptoms. The primary prediction model correctly indicated persistent symptoms in 71.0% of predictions (AUC 0.79). In patients with symptoms at baseline, cognitive-behavioral responses to symptoms predicted symptom persistence. Of various microbiological, immunological and genetic factors, only lower IL-10 concentrations in ex vivo stimulation experiments were associated with persistent symptoms. Clinical LB characteristics did not contribute to the prediction of persistent symptoms.
interpretationDeterminants of persistent symptoms after LB were mainly generic, including baseline functioning, symptoms and cognitive-behavioral responses. A potential role of host immune responses remains to be investigated.
fundingNetherlands Organisation for Health Research and Development (ZonMw); the Dutch Ministry of Health, Welfare and Sport (VWS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.